The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies.

Exo Therapeutics, US-based small molecule drug developer based on research at Harvard University and Salk Institute for Biological Studies, emerged from stealth yesterday having closed a $25m series A round featuring pharmaceutical firm Novartis, which invested through its Novartis Venture Fund. The round included 6 Dimensions Capital, the investment firm formed by the merger of…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.